Congress Presentations

Stay informed about the latest scientific and medical research from Axsome.

Filter

Sort

By Date

Anxiety and Depression Association of America (ADAA) 2024 Conference

Boston, MA | April 11 - 14, 2024

AXS-05 | Major Depressive Disorder

Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data from 3 Clinical Trials

View / Download

AXS-05 | Major Depressive Disorder

Dr. Craig Chepke, MD, DFAPA describes the “Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data from 3 Clinical Trials” ADAA 2024 poster

View

AXS-05 | Major Depressive Disorder

Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder

View / Download

AXS-05 | Major Depressive Disorder

Dr. Roger S McIntyre, MD, FRCPC describes the “Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder” ADAA 2024 poster

View

footer graphic

This site contains scientific information about investigational compounds and/or information about products and/or uses that have not been approved by the US Food and Drug Administration. The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.

AXSOME, AUVELITY, SUNOSI, SYMBRAVO and their logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2025 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, New York, NY 10007